Norva24 Group AB (Publ) SE0017084759 · Stock Open Norva24 Group AB (Publ) in new tab
Analyst price targets
Recent rating changes, newest first
Norva24 Group AB (Publ) Analysis (SE0017084759)
Is Norva24 Group AB (Publ) a good investment? Norva24 Group AB (Publ) (SE0017084759) is currently trading at 0.0694 SEK. Market analysts have a consensus price target of 34.10 SEK. This suggests a potential upside from current levels.
In terms of valuation, the stock trades at a P/E ratio of 26.49. This valuation is generally in line with the broader market.
Investor FAQ
Does Norva24 Group AB (Publ) pay a dividend?
No, it does not currently pay a dividend.
What asset class is Norva24 Group AB (Publ)?
Norva24 Group AB (Publ) is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.
Company Profile
Nexsen Limited operates as a nanobiotechnology company that develops proprietary biosensing platforms for rapid, high-precision point-of-care (POC) medical diagnostics and point-of-use sensing for human health, food and animal health, and biosecurity applications. The company offers Group B Streptococcus (GBS) rapid sensor; StrepSure, a diagnostic for the detection of human GBS in expectant mothers; kidney diseases, a POC tests for the screening, detection, and ongoing monitoring of various subsets of acute kidney injury and chronic kidney disease; bovine mastitis, a farm diagnostic to detect mastitis early which helps farmers; biosecurity pathogen tests, a portable sensor for frontline detection of invasive pests and pathogens -built for customs officers, farmers, and quarantine zones. It also offers rapid diagnostic programs targeting traumatic brain injury and neonatal sepsis. In addition, it is involved in developing rapid dual sensors for the detection of E.coli and Salmonella. The company was incorporated in 2021 and is based in Sydney, Australia.
Community Discussion